Skip to main content

Table 3 Quality assessment of registration information on special items (n, %)

From: Calling for improved quality in the registration of traditional Chinese medicine during the public health emergency: a survey of trial registries for COVID-19, H1N1, and SARS

No. Item name

COVID19 (n = 129)

H1N1 (n = 7)

Total (n = 136)

13. Interventions

 13.1 Intervention name

129 (100.0%)

7 (100.0%)

136 (100.0%)

 13.2 Ingredients or detail technique

13 (10.1%)

1 (14.3%)

14 (10.3%)

 13.3 Form

55 (42.6%)

4 (57.1%)

59 (43.4%)

 13.4 Dosage and frequency

20 (15.5%)

4 (57.1%)

24 (17.6%)

 13.5 Treatment duration

6 (4.7%)

0 (0.0%)

6 (4.4%)

 13.6 Control group

103 (79.8%)

7 (100.0%)

110 (80.9%)

 Total average

54.3 (42.1%)

3.8 (54.8%)

58.1 (42.7%)

14. Key inclusion and exclusion criteria

 14.1 Criteria of inclusion and exclusion

129 (100.0%)

7 (100.0%)

136 (100.0%)

 14.2 Gender

129 (100.0%)

7 (100.0%)

136 (100.0%)

 14.3 Age

109 (84.5%)

7 (100.0%)

116 (85.3%)

 14.4 Diagnosis criteria—Western medicine

45 (34.9%)

2 (28.6%)

47 (34.6%)

 14.5 With healthy human volunteer

1 (0.8%)

0 (0.0%)

1 (0.7%)

 Total average

82.6 (64.0%)

4.6 (65.7%)

87.2 (64.1%)

15. Study type

 15.1 Type of study

129 (100.0%)

7 (100.0%)

136 (100.0%)

 15.2 Method of allocation (randomized/non-randomized)

107 (82.9%)

5 (71.4%)

112 (82.4%)

 15.3 Masking (is masking used and, if so, who is masked)

46 (35.7%)

2 (28.6%)

48 (35.3%)

 15.4 Assignment (single arm, parallel, crossover, or factorial)

107 (82.9%)

7 (100.0%)

114 (83.8%)

 15.5 Allocation concealment mechanism

6 (4.7%)

0 (0.0%)

6 (4.4%)

 15.6 Phase (if applicable)

79 (61.2%)

5 (71.4%)

84 (61.8%)

 Total average

79.0 (61.2%)

4.3 (61.9%)

83.3 (61.3%)

19. Primary outcome(s)

 19.1 Name

128 (99.2%)

7 (100.0%)

135 (99.3%)

 19.2 Measurement of primary outcome(s)

2 (1.6%)

0 (0.0%)

2 (1.5%)

 19.3 Time point of measurements

17 (13.2%)

1 (14.3%)

18 (13.2%)

 Total average

49.0 (38.0%)

2.7 (38.1%)

51.7 (38.0%)

20. Key secondary outcome(s)

 20.1 Name

89 (69.0%)

7 (85.7%)

96 (70.6%)

 20.2 Measurements of key secondary outcomes

2 (1.6%)

0 (0.0%)

2 (1.5%)

 20.3 Time point of measurements

15 (11.6%)

1 (14.3%)

16 (11.8%)

 Total average

35.3 (27.4%)

2.7 (38.1%)

38.0 (27.9%)

21. Ethics review

 21.1 Ethics review status

125 (96.9%)

6 (83.3%)

131 (96.3%)

 21.2 Date of approval

98 (76.0%)

4 (69.0%)

102 (75.0%)

 21.3 Name of ethics committee(s)

105 (81.4%)

4 (78.6%)

109 (80.1%)

 21.4 Contact details of ethics committee(s)

104 (80.6%)

0 (40.5%)

104 (76.4%)

 Total average

108.0 (83.7%)

4.0 (57.1%)

112.0 (82.4%)

23. Summary results

 23.1 Date of posting of result summaries

0 (0%)

0 (0%)

0 (0%)

 23.2 Date of the first journal publication of results

0 (0%)

0 (0%)

0 (0%)

 23.3 URL hyperlink(s) related to results or a full reference list of publications

0 (0%)

0 (0%)

0 (0%)

 23.4 Baseline characteristics

0 (0%)

0 (0%)

0 (0%)

 23.5 Participant flow, adverse events

0 (0%)

0 (0%)

0 (0%)

 23.6 Adverse events

0 (0%)

0 (0%)

0 (0%)

 23.7 Outcome measures

0 (0%)

0 (0%)

0 (0%)

 23.8 URL link to protocol file(s) with version and date

0 (0%)

0 (0%)

0 (0%)

 Changes to protocol

0 (0%)

0 (0%)

0 (0%)

 Total average

0 (0%)

0 (0%)

0 (0%)

Total special items average report percentage (%)

45.6%

45.1%

45.6%

  1. COVID-19 severe acute respiratory syndrome coronavirus 2, H1N1 H1N1 influenza